Hit-To-Lead Optimization in Pancreatic Cancer

Hit-To-Lead Optimization in Pancreatic Cancer

Alfa Cytology is a full-scale contract research organization (CRO) with extensive experience. We are committed to providing a range of pancreatic cancer (PC) research and drug development services to our global clients ranging from pharmaceutical, biotechnology, and research institutions. Importantly, we can provide our services in a modular and integrated manner during the development of small molecule drugs according to our customers' requirements.

The service offering at Alfa Cytology

During the compound design and compound synthesis, a range of parameters must be fully understood and considered, including potency, stability, bioavailability, efficacy, selectivity, pharmacokinetics, pharmacodynamics, and so on. The optimization of a lead structure is mainly through iterative rounds of medicinal chemistry design, synthesis, and testing. Our small molecule drug discovery project team has years of experience in PC therapy and compound optimization, and we are well equipped to drive your program forward.

  • Medicinal chemistry platform
Medicinal chemistry platform

Through an in-depth understanding of the factors that influence the pharmacokinetics and the extensive use of structural biology and computational tools, Alfa Cytology is able to help our clients optimize the properties of their compounds in a comprehensive and rational manner. On our medicinal chemistry platform, a hypothesis-driven optimization is a powerful tool for driving compound optimization, including developing hypotheses to overcome problems and then interrogating those hypotheses in a cycle of design, synthesis, testing, and analysis.

  • Structure-based assessment platform

Size exclusion chromatography, X-ray crystallography, surface plasmon resonance (SPR), and nuclear magnetic resonance (NMR) are accessible to perform biophysical assays to find compound binding to candidate target proteins.

Preclinical cancer model platform
  • Preclinical cancer model platform

Several popular PC models are available at our company, including PC cell models, PC organoids, genetically engineered mouse models, and transplantation models. These models can be used to assist lead optimization.

  • Computer-aided drug design platform

Using advanced modeling techniques and data analysis methods, we can support small molecule inhibitor discovery for PC therapy from hit identification to lead optimization. In addition to supporting the design and optimization process, our computational chemistry team has years of experience deploying a suite of computer tools to assist in the interpretation of in vitro and in vivo data.

  • Synthetic chemistry platform

Our chemistry team consists of talented chemists who are able to ensure high compound productivity and maximum efficiency by using the latest synthetic chemistry methods and techniques with innovative synthetic route designs. Our synthetic chemistry capabilities include, but are not limited to, validation of synthetic routes, automated mass-oriented purification, multi-stage syntheses, and scale-up production.

Our service support

  • Optimize hits for desired potency and efficacy through hypothesis-driven optimization
  • Multi-objective optimization of leads, involving potency, stability, bioavailability, selectivity, pharmacokinetic/pharmacodynamic, and so on
  • Selection of preclinical candidates

Our services are based on in-depth scientific expertise, proven discovery platforms, and years of experience, supporting the optimization and translation of optimal solutions into single compounds to be delivered to our client partners. Thanks for your interest in our hit-to-lead optimization service, which is part of our integrated small molecule drug development for PC. In order to get more details about our services, please contact us. We've got everything covered for your needs.


  1. Hoelder, Swen, Paul A. Clarke, and Paul Workman. "Discovery of small molecule cancer drugs: successes, challenges and opportunities." Molecular oncology 6.2 (2012): 155-176.
  2. Fernandez-Vega, Virneliz, et al. "Lead identification using 3D models of pancreatic cancer." Slas Discovery 27.3 (2022): 159-166.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.